Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04688151 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Eligibility criteria expanded, about 52 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 1, 2021 to Feb 22, 2021
    • Study arms: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
Trial Details
NCT Number NCT04688151
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, National Cheng-Kung University Hospital, China Medical University Hospital, Chang Gung Memorial Hospital
Conditions
(from sponsor)		 Primary Central Nervous System Lymphoma (PCNSL)
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov